The pipeline of blood cancer treatments in clinical testing or being reviewed by the FDA includes 241 drugs, according to the Pharmaceutical Research and Manufacturers of America. Ninety-eight of the drugs are being developed for the treatment of lymphoma, while 97 are being developed for leukemia, 52 for multiple myeloma and 24 for other cancers of the bone marrow, blood and lymph nodes.

Full Story:
Drug Store News

Related Summaries